Insulin — Risks, Side Effects & Safer Alternatives

Insulin is a hormone that plays a crucial role in regulating blood sugar levels, and while it is an FDA-approved treatment for diabetes, some individuals outside of this medical context use injectable insulin for various personal goals. Common motivations include:

• Muscle Growth: Bodybuilders and athletes often seek insulin for its anabolic properties, believing it can enhance muscle mass by promoting nutrient uptake into cells.
• Fat Loss: Some users think that insulin can help manage body composition and fat loss when used strategically, although this is highly controversial and risky.
• Anti-Aging: There are claims that insulin can contribute to longevity and improved vitality, although scientific support for these claims is minimal.
• Cognitive Enhancement: Some individuals believe that insulin may improve cognitive function and mood, driving them to explore its off-label use.

Online communities often share anecdotal experiences and perceived benefits that drive interest in insulin use, including:

• Improved workout recovery times.
• Enhanced energy levels during intense exercise.
• The ability to manipulate body composition more effectively.

Despite these perceived benefits, the motivations for using insulin do not justify the significant risks involved. The drug carries a high risk level, with potential side effects that can be severe and life-threatening. These include:

• Hypoglycemia, which can be fatal if not managed properly.
• Fat gain, counteracting the intended goals of fat loss.
• Lethargy and diminished physical performance.
• Brain damage from severe hypoglycemic episodes.
• Death in extreme cases of mismanagement.

In conclusion, while some individuals may seek insulin for various outcomes, it is critical to recognize that the associated risks significantly outweigh any potential benefits outside of a medical context.

Insulin was first discovered in 1921 by Canadian scientists Frederick Banting and Charles Best at the University of Toronto. This groundbreaking discovery aimed to provide a treatment for diabetes, particularly Type 1 diabetes, which was previously a fatal condition. The original intended purpose of insulin was strictly pharmaceutical, to manage blood glucose levels in diabetic patients and improve their quality of life.

Insulin became widely available in the 1920s and revolutionized diabetes treatment, leading to a significant decrease in diabetes-related mortality rates. Over the decades, its use expanded beyond traditional medical settings, and by the late 20th century, it began to gain traction in wellness and biohacking communities. Individuals looking to enhance athletic performance and optimize body composition started to experiment with insulin for its anabolic properties, particularly in the realm of bodybuilding and fitness.

As of October 2023, insulin remains a regulated substance, classified as a prescription medication in most countries. Its use outside of prescribed medical contexts is often viewed with caution due to potential health risks and the ethical implications surrounding its misuse. Regulatory agencies continue to monitor its distribution and usage closely to avoid abuse and ensure patient safety.

Insulin, particularly in its injectable form, has been extensively studied as a primary treatment for diabetes management. Current scientific research indicates a robust understanding of insulin's pharmacodynamics and efficacy, primarily informed by numerous randomized clinical trials (RCTs) and systematic reviews.

Key findings from notable studies include the systematic review and meta-analysis published in 2021, which examined the effects of apple cider vinegar on lipid profiles and glycemic parameters, indicating potential adjunctive benefits in diabetes management. Additionally, a 2023 RCT compared tirzepatide, a dual GIP/GLP-1 receptor co-agonist, to insulin lispro in patients with type 2 diabetes, demonstrating superior glycemic control and weight reduction with tirzepatide. This highlights ongoing advancements in diabetes pharmacotherapy beyond traditional insulin therapy.

Evidence from human clinical trials, such as the 2022 Endocrine Society guidelines for managing hyperglycemia in hospitalized patients, underscores the critical role of insulin in acute care settings. Furthermore, a systematic review in 2018 on biosimilar insulins supports the efficacy of these alternatives compared to originator insulins. However, it is important to note that some studies, such as those investigating probiotics for glycemic control, indicate that while adjunct therapies may complement insulin treatment, they should not replace it.

Despite the wealth of human data, significant gaps remain in our understanding. For instance, the long-term effects of newer agents like tirzepatide compared to traditional insulins are not fully elucidated, particularly concerning safety profiles and potential risks of dementia highlighted in a 2024 umbrella review. Moreover, research primarily focuses on glycemic control without adequate exploration of quality of life and psychological impacts of insulin therapy in diverse populations.

In conclusion, while injectable insulin remains a cornerstone of diabetes management, ongoing research continues to explore the evolving landscape of diabetes therapeutics. We still do not fully understand the long-term implications of newer treatments compared to insulin, nor do we have comprehensive insights into the combined effects of adjunct therapies on overall patient outcomes.